Understanding Peptide Half-Life
What half-life means for peptides, why most are cleared so quickly, and how engineered analogs extend their duration of action.
Half-life is one of the most cited — and most misunderstood — numbers in peptide research. It describes how long a compound persists, and it explains why two peptides that hit the same receptor can behave completely differently.
What “half-life” actually means
The plasma half-life is the time it takes for the concentration of a compound in the bloodstream to fall by half. If a peptide has a half-life of 30 minutes, then 30 minutes after it peaks, roughly half remains; after another 30 minutes, a quarter; and so on. After about five half-lives, a compound is essentially cleared.
Why most peptides are short-lived
Native peptides are usually cleared within minutes. Several mechanisms work against them at once:
- Enzymatic degradation — peptidases and proteases in blood and tissue cleave peptide bonds rapidly. Dipeptidyl peptidase-4 (DPP-4), for example, inactivates native GLP-1 within minutes.
- Renal filtration — small peptides are filtered out by the kidneys quickly.
- Receptor-mediated clearance — binding and internalisation removes the peptide from circulation.
This is why the body’s own signalling peptides are released in tight, pulsatile bursts rather than maintained at steady levels.
How analogs last longer
Drug developers extend half-life deliberately, and the techniques recur across the peptides in this database:
- Amino acid substitution — swapping in a D-amino acid or an unnatural residue at a cleavage site blocks the enzyme that would otherwise cut it. This is how Mod GRF 1-29 resists degradation that native GHRH does not.
- Albumin binding — attaching a group that binds serum albumin (as in CJC-1295’s “DAC” technology, or the fatty-acid chains on semaglutide and tirzepatide) turns a molecule of minutes into one of days.
- Lipidation — fatty-acid acylation slows absorption and adds albumin affinity, the basis of the once-weekly incretin mimetics.
Why it matters for research
Half-life drives dosing frequency and the shape of the biological signal. A short-acting GHRP produces a sharp pulse that mimics natural physiology; a long-acting analog produces sustained exposure. Neither is universally “better” — they answer different research questions.
Provided for educational reference only. See our disclaimer.
Last reviewed: 2026-06-26. See our disclaimer.